Pharmaceutical compositions of spironolactone for deep dermal drug delivery - Patents.com

Abstract

A pharmaceutical composition for the topical administration of spironolactone to the pilosebaceous unit and a method for administering the same.The pharmaceutical composition comprises an aqueous suspension of submicron particles of spironolactone in water.

Description

[Technical field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims priority to U.S. Provisional Patent Application No. 63 / 278,377, filed November 11, 2021, and incorporated herein by reference.

[0002]

[0002] The subject matter disclosed herein generally relates to pharmaceutical compositions of spironolactone for topical administration of a drug to the pilosebaceous unit and methods for administering the same. As disclosed herein, the inventors of the present invention have made the surprising discovery that a pharmaceutical composition comprising small particles of spironolactone suspended in water can be targeted to the pilosebaceous unit after topical administration. [Background technology]

[0003]

[0003] Transdermal and topical delivery of drugs have various advantages over other routes of administration. Transdermal and topical delivery can be used to continuously deliver drugs to the systemic circulation and avoid first-pass metabolism. In contrast, oral drug delivery has a significant first-pass effect in the liver that can metabolize drugs early. Transdermal and topical delivery also have advantages over intravenous administration, which must be a sterile product and can be painful, increasing the rate of non-compliance by subjects. On the other hand, transdermal delivery can be non-sterile, non-invasive, and self-administered.

[0004]

[0004] Conventional drug delivery systems have focused on administration via the transepidermal delivery route. Andrea C. Lauer et al., Transfollicular Drug Delivery, Pharmaceutical Research 12:2 (1995). Skin is composed of four main layers: (a) the stratum corneum (nonviable epidermis), (b) the viable epidermis, (c) the dermis, and (d) the subcutaneous tissue. Skin also contains appendages in the form of terminal hairs, which may extend more than 3 mm into the subcutaneous fatty tissue below the skin surface, and vellus hairs, which are thin, often unrecognized body hairs that extend less than 1 mm into the dermis. The hair follicle, hair shaft, and sebaceous glands, which secrete a lubricating oil-like substance to the hair follicle, make up what is known as the pilosebaceous unit. Although the stratum corneum has traditionally been regarded as the main route for drug penetration, it is also the main barrier to transdermal absorption. In the past, researchers have questioned the importance of the pilosebaceous unit in drug delivery.

[0005] More recently, however, the potential role of the pilosebaceous unit and alternative mechanisms for transdermal delivery of drugs have been explored. Amit Verma et al., Transfollicular drug delivery: current perspectives, Research and Reports in Transdermal Drug Delivery (April 20, 2016). Mammalian hair follicles are complex, dynamic structures in which unique biochemical and immune responses occur. Although the pilosebaceous unit may be an acceptable target for drug delivery, several challenges exist for drug delivery to the pilosebaceous unit. One of the challenges associated with drug delivery to the pilosebaceous unit is the need to avoid the stratum corneum, which extends to a depth of approximately 10-20 μm, and the upper capillary network, which extends to a depth of approximately 80 μm. Summary of the Invention [Problem to be solved by the invention]

[0006]

[0006] Currently, there is a need for pharmaceutical compositions capable of penetrating deeper into the dermis, approximately 1,000 μm to 2,000 μm into the pilosebaceous unit. There is an unmet need for new pharmaceutical compositions and methods of administering drugs via the pilosebaceous unit. [Means for solving the problem]

[0007] The present invention relates to a pharmaceutical composition of spironolactone for topical administration of the drug to the pilosebaceous unit and a method for administering the same. The pharmaceutical composition comprises small particles of spironolactone suspended in water. The inventors of the present invention have surprisingly determined that an aqueous suspension of spironolactone can target the pilosebaceous unit after topical administration.

[0008] In a particular embodiment of the present invention, a pharmaceutical composition is provided comprising a therapeutically effective amount of spironolactone or a pharma- ceutically acceptable salt thereof and water. The spironolactone may have a primary particle size distribution characterized by a D90 value of less than about 6 μm, less than about 1 μm, or more preferably, less than about 0.25 μm. The spironolactone may further have a primary particle size distribution characterized by a D50 value of less than about 2.7 μm, less than about 0.75 μm, or more preferably, less than about 0.15 μm. The spironolactone may further have a primary particle size distribution characterized by a D10 value of less than about 1.2 μm, less than about 0.50 μm, or more preferably, less than about 0.10 μm.

[0009]

[0009] In certain embodiments, the pharmaceutical composition comprises about 0.10% w / w to about 7.5% w / w of spironolactone or a salt thereof. In certain embodiments, the pharmaceutical composition may comprise about 0.5% w / w to about 5% w / w of spironolactone or a salt thereof. In certain embodiments, the pharmaceutical composition is an aqueous suspension. In certain embodiments, the pharmaceutical composition further comprises dioctyl sodium sulfosuccinate and / or hydroxyl propyl cellulose. In certain embodiments, the pharmaceutical composition comprises about 0.01% w / w to about 1% w / w of dioctyl sodium sulfosuccinate and / or about 0.01% to about 1.5% w / w of hydroxyl propyl cellulose. In certain embodiments, the pharmaceutical composition is a topical formulation.

[0010] In certain embodiments, the pharmaceutical composition is capable of delivering spironolactone to the pilosebaceous unit of a subject. In certain embodiments, the pharmaceutical composition is capable of achieving a skin penetration of at least 1 mm in a subject, preferably about 2 or 3 mm in a subject.

[0011] In certain embodiments of the present invention, a pharmaceutical composition is provided that consists essentially of or consists of a therapeutically effective amount of spironolactone or a pharma- ceutically acceptable salt thereof, dioctyl sodium sulfosuccinate, hydroxypropylcellulose, and water. The spironolactone may have a primary particle size distribution characterized by a D90 value of less than about 6 μm, less than about 1 μm, or more preferably, less than about 0.25 μm. The spironolactone may further have a primary particle size distribution characterized by a D50 value of less than about 2.7 μm, less than about 0.75 μm, or more preferably, less than about 0.15 μm. The spironolactone may further have a primary particle size distribution characterized by a D10 value of less than about 1.2 μm, less than about 0.50 μm, or more preferably, less than about 0.10 μm.

[0012]

[0012] In certain embodiments, the pharmaceutical composition comprises about 0.10% w / w to about 7.5% w / w of spironolactone or a salt thereof. In certain embodiments, the pharmaceutical composition may comprise about 0.5% w / w to about 5% w / w of spironolactone or a salt thereof. In certain embodiments, the pharmaceutical composition is an aqueous suspension. In certain embodiments, the pharmaceutical composition comprises about 0.01% w / w to about 1% w / w of dioctyl sodium sulfosuccinate and about 0.01% to about 1.5% w / w of hydroxypropyl cellulose.

[0013] In certain embodiments, the pharmaceutical composition is capable of delivering spironolactone to the pilosebaceous unit of a subject. In certain embodiments, the pharmaceutical composition is capable of achieving a skin penetration of at least 1 mm in a subject, preferably about 2 or 3 mm in a subject.

[0014]

[0014] In certain embodiments, the pharmaceutical composition is provided in a package selected from the group consisting of a sachet containing a wet tissue or wipe containing a suspension, a pump containing a spray or foam, a control flow applicator with a sponge, or a dropper or dropper bottle.

[0015]

[0015] In certain embodiments of the present invention, a method of treating a skin or hair disorder in a subject in need thereof is provided. In certain embodiments, the skin or hair disorder is acne, alopecia areata, or androgenic alopecia. In certain embodiments, the subject is male or female. In certain embodiments for treating acne, the subject is female. The method comprises topically administering to the subject a pharmaceutical composition of spironolactone as described herein. In the methods of the present invention, spironolactone or a salt thereof can be delivered to the pilosebaceous unit. In the methods disclosed herein, administration of the pharmaceutical composition can result in skin penetration of spironolactone of at least 1 mm in the subject, preferably about 2 or 3 mm in the subject.

[0016]

[0016] The accompanying drawings, which are incorporated in this specification and form a part of this disclosure, serve to illustrate various embodiments of the present invention and, together with the description, further serve to explain the invention to enable those skilled in the art to make and use the embodiments disclosed herein. [Brief description of the drawings]

[0017] [Figure 1] FIG. 1 shows particle size distribution of spironolactone in a suspension of 5.0% nanomilled spironolactone in water containing 0.05% dioctyl sulfosuccinate (DOSS) and 1.0% hydroxypropyl cellulose. [Diagram 2]

[0018] FIG. 1 is a photomicrograph taken after two weeks of storage following completion of milling of a 5% spironolactone suspension that was roller milled to form a suspension with a D90 of approximately less than 5 μm. [Diagram 3]

[0019] FIG. 1 is a photomicrograph taken after two weeks of storage following completion of milling of a 5% suspension of spironolactone in a 94.5:0.5 wt:wt mixture of cyclomethicone and dioctyl sodium sulfosuccinate that was roller milled to form a suspension with a D90 of approximately less than 5 μm. [Figure 4]

[0020] FIG. 1 shows the cumulative amount of spironolactone that appeared in the receptor solution over a 24-hour period following a single dose of 5.0 μL per cell (10 mg per cm2 of skin tissue) for an exemplary aqueous suspension formulation (Formulation 1), Emulsion 1, Emulsion 2, and a comparative gel formulation (as described in further detail in Example 2). [Diagram 5]

[0021] FIG. 1 shows the amount of spironolactone (ng) in the epidermis and dermis after 24 hours for an exemplary aqueous suspension formulation (Formulation 1), Emulsion 1, Emulsion 2, and a comparative gel formulation (as described in Example 2). [Figure 6]

[0022] FIG. 1 shows the average amount of spironolactone that appeared in the receptor solution over 24 hours following a single dose of 5.0 μL per cell (10 mg per cm2 of skin tissue) for eight exemplary formulations (S1-S7 described in Example 3 and formulation 1 described in Example 2). [Figure 7]

[0023] FIG. 1 shows the amount of spironolactone (ng) in the epidermis and dermis after 24 hours for eight exemplary formulations (S1-S7 described in Example 3 and formulation 1 described in Example 2). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0018]

[0024] Before the present invention is described in detail below, it should be understood that the present invention is not limited to the specific methodology, protocols, and reagents described herein, as these may vary. It should also be understood that the terms used herein are for the purpose of describing specific embodiments only, and are not intended to limit the scope of the present invention, which will be limited only by the appended claims. Unless otherwise specified, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.

[0019]

[0025] All publications, patents, and patent applications cited herein are incorporated herein by reference in their entirety unless otherwise stated. Where the same term is defined in a publication, patent, or patent application and in this disclosure incorporated herein by reference, the definition in this disclosure represents the controlling definition. With respect to publications, patents, and patent applications referenced to describe a particular type of compound, chemical property, etc., the portion related to such compound, chemical property, etc. is the portion of the document incorporated herein by reference.

[0020]

[0026] As used herein, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, an "active ingredient" includes one ingredient as well as two or more different ingredients, and "sulfate" includes one sulfate as well as two or more different sulfate salts.

[0021]

[0027] When used in connection with a numerical value, the term "about" is intended to encompass numerical values ​​in a range having a lower limit of 5% below the indicated numerical value and an upper limit of 5% above the indicated numerical value.

[0022]

[0028] The term "effective" refers to an amount of a compound, agent, substance, formulation, or composition that is sufficient to result in a decrease in the severity of disease symptoms, an increase in the frequency and duration of symptom-free periods of the disease, or prevention of impaired function or disability due to the affliction of the disease. The amount may be as a single dose alone or in combination with other compounds, agents, or substances, or according to a multiple dose regimen. One of skill in the art will be able to determine such amounts based on factors such as the size of the subject, the severity of the subject's symptoms, and the particular composition or route of administration selected.

[0023]

[0029] "Pharmaceutically acceptable" means generally safe for administration to humans or animals. Preferably, a pharmaceutically acceptable ingredient is one that has been approved by a federal or state government regulatory agency for use in animals, more specifically humans, or is listed in the United States Pharmacopeia, as promulgated by the United States Pharmacopeial Convention, Inc., Rockville Md., or other generally recognized pharmacopoeias.

[0024]

[0030] A "pharmaceutical composition" according to the invention may be in the form of a composition in which the different active ingredients and the diluents and / or carriers are mixed with one another, or it may take the form of a combined preparation in which the active ingredients are present in a partially separate or completely separate form. An example for such a combination or combined preparation is a kit of components.

[0025]

[0031] As used herein, the term "subject" or "patient" most preferably refers to a human. The term "subject" or "patient" may include any mammal that may benefit from the compounds described herein.

[0026]

[0032] A "therapeutic amount" or a "therapeutically effective amount" is an amount of a therapeutic agent sufficient to achieve its intended purpose. The effective amount of a given therapeutic agent will vary depending on factors such as the nature of the agent, the route of administration, the size of the subject to which the therapeutic agent is administered, and the purpose of the administration. The effective amount in each individual case may be determined empirically by the skilled artisan according to methods established in the art.

[0027]

[0033] The term "topical" with respect to administration of a drug or composition refers to application of such drug or composition to an epithelial surface that is external to the body, including the skin or cornea. In this regard, application inside a body orifice, such as the mouth, vagina, or rectum, whose mucosal surface does not contain pilosebaceous units, is not considered a topical application.

[0028]

[0034] As used herein, "treat," "treating," or "treatment" of a disease or disorder means achieving one or more of the following: (a) reducing the severity and / or duration of the disorder; (b) limiting or preventing the occurrence of symptoms characteristic of the disorder being treated; (c) arresting the worsening of symptoms characteristic of the disorder being treated; (d) limiting or preventing the recurrence of the disorder in a subject who previously had the disorder; (e) limiting or preventing the recurrence of symptoms associated with the disorder in a subject who previously exhibited symptoms associated with the disorder; and (f) ameliorating symptoms characteristic of the disorder or symptoms associated with the disorder in a subject.

[0029]

[0035] The abbreviation "w / w" refers to the relative concentration of ingredients in a composition as "weight to weight" (i.e., percentages refer to percentages of the total weight) and not on a volume or other quantity basis.

[0030]

[0036] The present invention relates to a pharmaceutical composition of spironolactone for topical administration of drugs to the pilosebaceous unit and a method for administering the same.The pharmaceutical composition comprises small particles of spironolactone and water.In certain embodiments, the pharmaceutical composition of the present invention is capable of delivering its active pharmaceutical ingredient to the pilosebaceous unit.In certain embodiments, the active pharmaceutical ingredient is capable of achieving at least 1 mm of skin penetration in a subject.

[0031]

[0037] In certain embodiments of the invention, the pharmaceutical composition comprises 17-hydroxy-7α-mercapto-3-oxo-17α-pregn-4-ene-21-carboxylic acid γ-lactone acetate, an aldosterone agonist, also known as spironolactone. The structure of spironolactone is:

[0032] [ka]

[0033] It is.

[0034]

[0038] Spironolactone is a drug that acts by competitively inhibiting the binding of aldosterone at the mineralocorticoid receptor level. This steroidal compound has been used to block aldosterone-dependent sodium transport in the distal tubules of the kidney to reduce edema and treat essential hypertension and primary hyperaldosteronism. Orally administered spironolactone is also effective in treating women with acne. EMAttwa et al., Efficacy and safety of topical spironolactone 5% gel versus placebo in the treatment of acne vulgaris, J. Dermatol. Venerol. 39:89-94 (2019); JW Charny et al., Spironolactone for the treatment of acne in women, a retrospective study of 110 patients, Int. J. Womens Dermatol. 3(2):111-115 (2017). Spironolactone is commercially available under the trade names ALDACTONE® and CAROSPIR®. Spironolactone is disclosed in U.S. Patent No. 3,013,012, which is incorporated herein by reference.

[0035]

[0039] In the present invention, the pharmaceutical composition is administered topically.The pharmaceutical composition can be spironolactone as free base or pharmaceutical acceptable salt.Suitable pharmaceutical acceptable salts can be found in Remington's Pharmaceutical Sciences, 17th Edition, Mack Publishing Company (1985), which is incorporated herein by reference.

[0036]

[0040] The pharmaceutical may contain the active ingredient (i.e., spironolactone) as small or submicron particles. The particle size of the drug may be evaluated using laser diffraction. Laser diffraction is accepted by standards and guidance bodies including ISO and ASTM and is widely used to determine particle size distribution. In performing the evaluation, the sample is passed through a laser beam, which scatters the laser light at various angles. Multiple detectors placed at fixed angles measure the intensity of the scattered light at their locations. A mathematical model is then applied to generate the particle size distribution. The particle size values ​​reported herein are determined by using liquid dispersion or wet dispersion methods.

[0037]

[0041] In particle size measurement, the median is defined as the value above which half of the population lies and below which half lies. In particle size distribution, the median is referred to as D50. D50 is the size that divides the distribution into upper and lower halves of this diameter. This distribution width can also be characterized by quoting some combination of one, two, or three values ​​on the x-axis, typically D10, D50, and D90. D50, or the median, is defined above as the diameter below which half of the population lies. Similarly, 90 percent of the distribution lies below D90 and 10 percent of the population lies below D10.

[0038]

[0042] In certain embodiments, the pharmaceutical composition comprises spironolactone having a primary particle size distribution characterized by a D90 value of less than about 6 μm, less than about 5 μm, less than about 2 μm, less than about 1 μm, less than about 0.5 μm, less than about 0.25 μm, or more preferably less than about 0.2 μm. In certain embodiments, the spironolactone has a primary particle size distribution characterized by a D90 value between about 0.001 μm, 0.01 μm, or 0.1 μm and about 0.2 μm, 0.25 μm, 0.5 μm, 1 μm, 2 μm, 5 μm, or 6 μm.

[0039]

[0043] The spironolactone may further have a primary particle size distribution characterized by a D50 value of less than about 2.7 μm, less than about 2.0 μm, less than about 1.0 μm, less than about 0.75 μm, 0.5 μm, less than about 0.25 μm, less than about 0.2 μm, or more preferably less than about 0.15 μm. In certain embodiments, the spironolactone has a primary particle size distribution characterized by a D50 value between about 0.001 μm, 0.01 μm, or 0.1 μm and about 0.15 μm, 0.2 μm, 0.25 μm, 0.5 μm, 0.75 μm, 1.0 μm, 2.0 μm, or 2.7 μm.

[0040]

[0044] The spironolactone may further have a primary particle size distribution characterized by a D10 value of less than about 1.2 μm, less than about 1.0 μm, less than about 0.5 μm, less than about 0.25 μm, less than about 0.15 μm, less than about 0.10 μm, or more preferably less than about 0.08 μm. In certain embodiments, the spironolactone has a primary particle size distribution characterized by a D10 value between about 0.0001 μm, 0.001 μm, or 0.01 μm and about 0.10 μm, 0.15 μm, 0.25 μm, 0.5 μm, 1.0 μm, or 1.2 μm.

[0041]

[0045] In certain embodiments, the pharmaceutical composition is a suspension in which the active ingredient (i.e., spironolactone) is suspended in water. In certain embodiments, the pharmaceutical composition comprises between about 90%-99% w / w water. In certain embodiments, the pharmaceutical composition consists essentially of or consists of spironolactone, dioctyl sodium sulfosuccinate, hydroxyl propyl cellulose, and water. In certain embodiments, the pharmaceutical composition does not include added thickening agents or preservatives.

[0042]

[0046] In certain embodiments, the pharmaceutical composition may be formulated with additional ingredients, including ingredients conventionally found in topical cosmetic and medicinal products, hi certain embodiments, the additional ingredients comprise no more than 3%, 2%, 1%, or 0.5% w / w of the pharmaceutical composition.

[0043]

[0047] In certain embodiments, the pharmaceutical composition further comprises dioctyl sodium sulfosuccinate. In certain embodiments, the pharmaceutical composition further comprises hydroxyl propyl cellulose. In certain embodiments, the pharmaceutical composition comprises about 0.01% w / w to about 1% w / w dioctyl sodium sulfosuccinate and / or about 0.01% to about 1.5% w / w hydroxyl propyl cellulose.

[0044]

[0048] In certain embodiments, the pharmaceutical composition further comprises one or more of hydroxypropylmethylcellulose (HPMC), polyvinylpyrrolidone (PVP K30), a poloxamer such as poloxamer 407, and a polysorbate such as polysorbate 80. In certain embodiments, the pharmaceutical composition comprises about 0.1% to about 1.5% HPMC. In certain embodiments, the pharmaceutical composition comprises about 0.1% to about 1.5% PVP K30. In certain embodiments, the pharmaceutical composition comprises about 0.1% to about 1.5% poloxamer 407. In certain embodiments, the pharmaceutical composition comprises about 0.1% to about 1.5% polysorbate 80. In certain embodiments, the pharmaceutical composition comprises a pharma- ceutically acceptable cellulose polymer such as methylcellulose (MC), ethylcellulose (EC), hydroxyethylcellulose (HEC), carboxymethylcellulose (CMC), sodium carboxymethylcellulose (NaCMC), and microcrystalline cellulose. In certain embodiments, the pharmaceutical composition comprises from about 0.1% to about 1.5% of the cellulose polymer.

[0045]

[0049] Surfactants

[0050] In certain embodiments, the pharmaceutical composition may include one or more surfactants or co-surfactants.Surfactants include, but are not limited to, short chain alcohols, alkanediols and alkanetriols, alkyl phosphate esters, polyethylene glycols and polyethylene glycol ethers, polyethylene stearyl ethers including those sold under the trade names Brij S2, Brij S20, Brij 721, Brij 38, Brij 52, Brij 56, and Brij W1, pyrrolidine derivatives, bile salts, sorbitan fatty acid esters, and polyoxyethylene sorbitan fatty acid esters.In a preferred embodiment, the surfactant is dioctyl sodium sulfosuccinate.

[0046]

[0051] Polymers and Thickeners

[0052] In certain embodiments, the pharmaceutical compositions may include insoluble organic polymeric thickeners such as natural and synthetic polymers or inorganic thickeners such as acrylic acid copolymers, carbomer 1382, carbomer copolymer type B, carbomer homopolymer type A, carbomer homopolymer type B, carbomer homopolymer type C, acrylamide / sodium acryloyldimethyltaurate copolymer, carboxyvinyl copolymer, carboxymethylcellulose, carboxypolymethylene, carrageenan, guar gum, xanthan gum, hydroxyethylcellulose, hydroxypropylcellulose, microcrystalline wax, and methylcellulose.

[0047]

[0053] Additional Ingredients

[0054] In certain embodiments, the pharmaceutical compositions may include additional ingredients such as carriers and excipients conventionally found in topical cosmetic and medicinal products. Additional ingredients may be added to the composition, including, but not limited to, antioxidants (e.g., BHT, BHA, ascorbic acid, tocopherol, citric acid, propyl gallate, sodium metabisulfite), sequestrants, stabilizers, buffers, pH adjusters (preferably those that provide an acidic pH, including, but not limited to, gluconolatone, citric acid, lactic acid, and alpha hydroxy acids), skin penetration enhancers, skin protectants (including, but not limited to, petrolatum, paraffin wax, dimethicone, glyceryl monoisostearate, isopropyl isostearate, isostearyl isostearate, cetyl alcohol, potassium cetyl phosphate, cetyl behenate, and behenic acid), chelating agents, suspending agents (e.g., xanthan gum), colors, pigments, diluents, fragrances, and other excipients to improve stability or aesthetics.

[0048]

[0055] Administration and Dosage

[0056] The present invention further provides a method of treatment involving administration of one of the pharmaceutical compositions described herein.This method of treatment can be used to treat subjects suffering from disorders known to be treated with spironolactone.In certain embodiments, the method is for treating subjects suffering from skin or hair disorders selected from the group consisting of acne, alopecia (including alopecia areata and androgenetic alopecia), male pattern baldness, hirsutism, rosacea, and combinations thereof.The method involves topically administering to subjects a therapeutically effective amount of the pharmaceutical composition of spironolactone described herein.

[0049]

[0057] In certain embodiments, the present invention provides a method for treating acne in a subject in need of acne treatment. The method may include treating acne in a subject in need of acne treatment by administering to the subject a composition of spironolactone as described herein. Acne is a disorder of the pilosebaceous unit located on the face, chest, and back. The acne may be one selected from the group consisting of acne vulgaris, inflammatory acne, non-inflammatory acne, acne fulminans, nodular papulopustular acne, confluent acne, acne rosacea, rosacea, self-inflicted acne, adult-onset acne, persistent-recurrent acne after teenage years, and acne associated with other disorders. In certain embodiments, the subject is a male or female subject. In a preferred embodiment, the subject is a female. Additionally, subjects may (a) be experiencing acne flare-ups that cycle with menstruation, (b) be suffering from adult-onset acne or persistent-recurrent acne after the teenage years, even in the absence of clinical or laboratory signs of hyperandrogenism, (c) be taking oral contraceptives and present with moderate to severe acne that has a particular clinical hormonal pattern, or (d) be unresponsive to conventional treatments and are not candidates for oral isotretinoin therapy.

[0050]

[0058] In certain embodiments, the present invention provides a method for treating alopecia in a subject that needs to be treated.The method can include treating alopecia in a subject that needs to be treated by administering the composition of spironolactone described herein to the subject.The alopecia can be any form of alopecia, including alopecia areata or androgenetic alopecia.In terms of alopecia areata, treating this disorder includes recovering or preventing hair loss.

[0051]

[0059] In certain embodiments, the present invention provides a method for treating androgenetic alopecia in a subject in need of such treatment.The method can include treating androgenetic alopecia in a subject in need of such treatment by administering to the subject the spironolactone composition described herein.

[0052]

[0060] In the above embodiments, the method for treating a subject in need thereof comprises topically applying to the subject a therapeutically effective amount of a spironolactone pharmaceutical composition described herein. In certain embodiments, the active ingredient spironolactone may be administered in a therapeutically effective amount. In certain embodiments, the amount of spironolactone may range from about 0.01% w / w to about 10% w / w, or from about 0.01% w / w to about 7.5% w / w, or from about 0.01% w / w to about 5% w / w, or from about 0.1% w / w to about 3% w / w. Exemplary ranges are from about 0.1% w / w to about 10% w / w, or from about 0.1% w / w to about 7.5% w / w, or from about 0.1% w / w to about 5% w / w, or from about 0.1% w / w to about 3% w / w, or from about 1.0% w / w to about 5.0% w / w, or from about 0.3% w / w to about 5.0% w / w. For example, topical formulations may contain any of the following w / w percentages of spironolactone: 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1.0%, 1.1%, 1.2%, 1.3%, 1.4%, 1.5%, 1.6%, 7%, 1.8%, 1.9%, 1.0%, 2.1%, 2.2%, 2.3%, 2.4%, 2.5%, 2.6%, 2.7%, 2.8%, 2.9%, 3.0%, 3.1%, 3.2%, 3.3%, 3.4%, 3.5%, 3.6%, 3.7%, 3.8%, 3.9%, 4.0%, 4.1%, 4.2%, 4.3%, 4.4%, 4.5%, 4.6%, 4.7%, 4.8%, 4.9%, 5.0%, 5.1%, 5.2%, 5.3%, 5.4%, 5.5%, 5.6%, 5.7%, 5.8%, 5.9%, 6.0%, 6.1%, 6.2%, 6.3%, 6.4%, 6.5%, 6.6%, 6.7%, 6.8%, 6.9%, 7.0%, 7.1%, 7.2%, 7.3%, 7.4%, 7.5% etc.

[0053]

[0061] In certain embodiments, the pharmaceutical composition is administered topically according to a regimen, such as at regular intervals. For example, the topical pharmaceutical composition can be administered once a day, twice a day, three times a day, once a week, twice a week, three times a week, or four times a week. The pharmaceutical composition can be administered for a prescribed period of time. For example, the topical pharmaceutical composition can be administered for a period of about 2 weeks to at least about 6 months, or until an improvement in the skin condition or disease is visible. Exemplary periods of treatment regimen include 2 weeks, 1 month, 6 weeks, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, or 1 year. In a preferred embodiment, the topical pharmaceutical composition is administered twice or three times a day for a period of at least 3 months, 4 months, 5 months, or 6 months.

[0054]

[0062] Packaging containing a pharmaceutical composition

[0063] The spironolactone pharmaceutical compositions described herein may be formulated in a form suitable for topical application to the skin, including, for example, an aerosol, a dropper, a gel, a patch, a pump spray, an applicator, a wipe, or a wipe.The present invention further provides a package that includes one of the pharmaceutical compositions described herein.The package may be supplied in a variety of colors, materials, and sizes that will be understood by those skilled in the art to be most suitable for the intended application.

[0055]

[0064] In certain embodiments, the packaging is a sachet containing a wipe or wipes comprising one of the spironolactone pharmaceutical compositions described herein. In certain embodiments, the wipe or wipe is about 129.0 to 258.1 cm 2 (20-40 sq. in.), approx. 161.2-225.8 cm 2 (25-35 square inches), or approximately 193.5 cm 2(30 square inches). In certain embodiments, the towelette or wipe is about 5 inches by 6 inches. In certain embodiments, the towelette or wipe contains about 6-8 mL of the spironolactone composition, about 6-7.5 mL, about 6.5-7.5 mL of the spironolactone composition, or about 7 mL of the spironolactone composition. In certain embodiments, the towelette or wipe is about 6.45 cm by 15.24 cm. 2 (per square inch), about 0.2 to 0.4 mL, about 0.2 to about 0.3 mL, or about 0.25 mL of the spironolactone composition.

[0056]

[0065] In certain embodiments, the package is a mechanical pump that contains a foam or spray that contains one of the spironolactone compositions described herein.In certain embodiments, the pump is a polyethylene terephthalate mechanical pump that contains spironolactone foam.In certain embodiments, the pump is a sprayer pump that includes a clear glass or plastic bottle with a mist sprayer that contains spironolactone suspension.

[0057]

[0066] In certain embodiments, the packaging is a dropper or dropper bottle containing one of the spironolactone compositions described herein. In certain embodiments, the bottle is a low density polyethylene ("LDPE") bottle with a dropper tip.

[0058]

[0067] In certain embodiments, the package includes one of the spironolactone compositions described herein and includes a flow-controlled applicator with a sponge. The flow-controlled applicator may be any flow-controlled applicator known in the art, including those manufactured by Dab-O-Matic®. The flow-controlled applicator may include a variety of covers or caps, including those made of white nylon or polyethylene, that cover the neoprene sponge. In certain embodiments, the polyethylene cover allows for a moderate flow rate and allows larger particles to be dispensed without clogging the applicator head. The spring may be made of either high or low density polyethylene material to vary the amount of product dispensed.

[0059]

[0068] The following examples illustrate, but do not limit, certain embodiments of the present invention. EXAMPLES

[0060]

[0069] While various embodiments have been described above, it should be understood that they have been presented by way of example only, and not limitation. Thus, the breadth and scope of the present disclosure should not be limited by any of the above exemplary embodiments. In addition, any combination of all possible variations of the above elements is encompassed by the present disclosure unless otherwise indicated herein or clearly contradicted by context.

[0061]

[0070] Example 1

[0071] A 50 mg / mL aqueous suspension of 5% spironolactone containing 0.5% dioctyl sodium sulfosuccinate and 1% hydroxypropylcellulose was successfully nanomilled to form a stable suspension of submicron drug particles after 2 weeks of storage at 5° C. and ambient light. The spironolactone had the particle size distribution specified in FIG. 1. A Horiba Laser Scattering Particle Size Distribution Analyzer Model LA-950 was used to determine the volumetric distribution profile of spironolactone. All circulation, stirring, and sonication were turned off and the instrument was set to repeat mode per the instruction manual.

[0062]

[0072] Example 2

[0073] A 5.0%-5.5% spironolactone suspension in water containing 0.05%-0.055% dioctyl sodium sulfosuccinate and 1.0-1.1% hydroxylpropylcellulose was nanomilled to obtain the particle size distribution shown in Figure 1. The composition of the final product suspension is set forth in Table 1 as Formulation 1. An emulsion was formed by mixing the excipients disclosed in Table 1 as Emulsion 1. SEPINEO™ P600 is a thickening, emulsifying, and stabilizing polymer, acrylamide / sodium acryloyldimethyltaurate copolymer / isohexadecane & polysorbate 80, distributed by Seppic Inc., Fairfield NJ. Table 1 lists the final composition of Emulsion 1, where the cyclomethicone oil phase is a 5% spironolactone suspension in cyclomethicone, which was roller milled to form a suspension with a D90 of less than about 5 μm, as shown in FIG. 2 (micrograph taken after 2 weeks storage after milling was completed). Table 1 also lists the final composition of Emulsion 2, where the cyclomethicone oil phase is a 5% spironolactone suspension in a 94.5:0.5 wt:wt mixture of cyclomethicone and dioctyl sodium sulfosuccinate, which was roller milled to form a suspension with a D90 of less than about 5 μm, as shown in FIG. 3 (micrograph taken after 2 weeks storage after milling was completed). Comparative gel formulations described in the literature were prepared and are listed in Table 1 as comparative gels. (Attwa EM, Ibrahim AM, Abd El-Halim MF, Mahmoud HM, Efficacy and safety of topical spironolactone 5%gel versus placebo in the treatment of acne vulgaris, Egypt J Dermatol Venerol(2019);39:89~94.)

[0063] [Table 1]

[0064]

[0075] An in vitro skin permeation test (IVPT) was used to measure how quickly different formulations penetrate excised human skin. Human cadaveric skin was obtained from two donors (Caucasian female age=48 dermatome harvested abdominal skin with average thickness of 580 μm and Hispanic male age=50 dermatome harvested abdominal skin with average thickness of 910 μm). Dermatome harvested skin was obtained frozen from the United States Tissue Bank and stored at -20°C until use. Skin was cut into 0.503 cm sections. 2 The receptor solutions were then loaded onto vertical Franz cells with a diffusion area of ​​1.5 mm (8 mm diameter) and a receptor chamber filled with 3.0 mL of 4% BSA in water containing 0.01% gentamicin sulfate and thermostated at 32°C. Five microliters of each formulation was administered to each Franz cell using a positive displacement pipette (10 mg per square centimeter of skin). The receptor solutions were analyzed using a validated LC-MS / MS (Kinetex C18, 5 μm, 2.1×50 mm column, Shimadzu LC20ADXR pump and AB Sciex API4000 Turbo Spray detector). The measured cumulative amount of spironolactone in the receptor solution is the average of four replicate IVPT measurements.

[0065]

[0076] Twenty-four hours after skin application, all unabsorbed and unpenetrated spironolactone was removed from the skin surface to determine the levels of spironolactone retained in the epidermis and dermis. This was achieved by wiping the tissue surface three times with a Q-tip moistened with 1×PBS, followed by two tape strips. The epidermis (including the stratum corneum) was separated from the dermis and immersed overnight at room temperature in 4.0 mL of DMSO / acetonitrile (ACN) (50 / 50 v / v) mixture using an orbit shaker. The remaining dermal layer was cut into small pieces and extracted overnight at room temperature with 4.0 mL of DMSO / ACN mixture using an orbit shaker. The dermal and epidermal extracts were analyzed using a validated LC-MS / MS (Kinetex C18, 5 μm, 2.1×50 mm column, Shimadzu LC20ADXR pump and AB Sciex API4000 Turbo Spray detector).

[0066]

[0077] FIG. 4 shows the results for Formulation 1, Emulsion 1, Emulsion 2, and the comparative gel at 5.0 μL per cell (1 cm of skin tissue). 2Figure 4 shows the cumulative amount of spironolactone that appeared in the receptor solution over 24 hours after a single dose of 10 mg / ml (100 mg / ml). In Figure 4, each plotted value is the average of four separate pieces of excised human skin. Figure 5 shows the amount of spironolactone (ng) in the epidermis and dermis at 24 hours for Formulation 1, Emulsion 1, Emulsion 2, and the Comparative Gel. As can be seen in Figure 5, the Comparative Gel containing 5% dissolved spironolactone delivered more spironolactone through the excised human skin than either the 5% spironolactone aqueous suspension or either of the two emulsion formulations. However, significantly more accumulation of spironolactone in the epidermis (at the infundibulum of the pilosebaceous unit) is seen in Figure 5 for the aqueous suspension compared to the Comparative Gel with dissolved spironolactone or the silicone oil emulsion with suspended submicron particles of spironolactone. The high levels of API in the epidermis and dermis suggest that spironolactone targets the pilosebaceous unit with significantly greater follicular accumulation from the aqueous suspension (D90<0.5 μm for Formulation 1).

[0067]

[0078] Example 3

[0079] A 5.0%-5.5% spironolactone suspension in water containing 0.05%-0.055% dioctyl sodium sulfosuccinate and 1.0-1.1% hydroxylpropylcellulose was nanomilled to obtain the particle size distribution shown in Figure 1. To this aqueous suspension, different preservatives, thickeners, and ethanol were added as shown in Table 2. Seven different formulations (S1-S7) were prepared as specified in Table 2.

[0068] [Table 2]

[0069]

[0081] An in vitro skin permeation test (IVPT) was used to measure how quickly different formulations penetrate excised human skin. Human cadaveric skin was obtained from two donors (Caucasian female age=44 dermatome harvested abdominal skin with average thickness of 710 μm and Caucasian female age=48 dermatome harvested abdominal skin with average thickness of 578 μm). The dermatome harvested skin was obtained frozen from the United States Tissue Bank and stored at -20°C until use. The skin was cut into 0.503 cm sections. 2 The receptor solutions were then loaded onto vertical Franz cells with a diffusion area of ​​1.5 mm (8 mm diameter) and a receptor chamber filled with 3.0 mL of 4% BSA in water containing 0.01% gentamicin sulfate and thermostated at 32°C. Five microliters of each formulation was administered to each Franz cell using a positive displacement pipette (10 mg per square centimeter of skin). The receptor solutions were analyzed using a validated LC-MS / MS (Kinetex C18, 5 μm, 2.1×50 mm column, Shimadzu LC20ADXR pump and AB Sciex API4000 Turbo Spray detector). The measured cumulative amount of spironolactone in the receptor solution is the average of four replicate IVPT measurements.

[0070]

[0082] Twenty-four hours after skin application, all unabsorbed and unpenetrated spironolactone was removed from the skin surface to determine the levels of spironolactone retained in the epidermis and dermis. This was achieved by wiping the tissue surface three times with a Q-tip moistened with 1×PBS, followed by two tape strips. The epidermis (including the stratum corneum) was separated from the dermis and immersed overnight at room temperature in 4.0 mL of DMSO / acetonitrile (ACN) (50 / 50 v / v) mixture using an orbit shaker. The remaining dermal layer was cut into small pieces and extracted overnight at room temperature with 4.0 mL of DMSO / ACN mixture using an orbit shaker. The dermal and epidermal extracts were analyzed using a validated LC-MS / MS (Kinetex C18, 5 μm, 2.1×50 mm column, Shimadzu LC20ADXR pump and AB Sciex API4000 Turbo Spray detector).

[0071]

[0083] FIG. 6 shows that for S1-S7 and formulation 1 (as described in Example 2), 5.0 μL per cell (1 cm of skin tissue) 2 Figure 6 shows the average amount of spironolactone that appeared in the receptor solution over a 24-hour period after a single dose of 10 mg per microgram of human skin. In Figure 6, each plotted value is the average of four separate pieces of excised human skin. Figure 6 shows the amount of spironolactone (ng) in the epidermis and dermis after 24 hours for S1-S7 and Formulation 1 (as described in Example 4). Figure 7 shows that after topical administration of the aqueous suspension (Formulation 1), there is a significantly greater accumulation of spironolactone in the epidermis and dermis compared to the seven other formulations (S1-S7) with the same particle size distribution as specified in Figure 1. This data suggests that even minor modifications such as the addition of a preservative or gelling agent inactivate the ability of suspended spironolactone to target the pilosebaceous unit.

[0072]

[0084] Example 4

[0085] Sachets containing spironolactone suspension wipes were prepared. Individual wipes and sachets were cut from bulk rolls of two different brands of product packaging (package types "A" and "B"). The sachets were formed by heat sealing three edges of a paper (outer) / foil (inner) laminate roll of material. Packaging type A was in the form of a 2 inch by 3.75 inch pouch and packaging type B was in the form of a 2.5 inch by 3 inch pouch. Wipes measuring 5 inches by 6 inches were folded 5.5 times into an accordion shape, then folded in half and placed into the corresponding pouch, and the final edge of the package was heat sealed.

[0073]

[0086] A batch of 5.49% spironolactone nano-sized suspension in water containing 0.055% dioctyl sodium sulfosuccinate, 1.1% hydroxylpropylcellulose, 0.10% methylparaben, and 0.01% propylparaben was prepared. A 5 inch by 6 inch wipe was dosed with either 3.9 mL or 7.8 mL of spironolactone suspension, the sachet was sealed, and the completed unit was stored at controlled room temperature ("CRT") for at least 2 days ("NLT") prior to testing. The wipes were subjected to measurements to determine the amount of spironolactone successfully recovered from the wipe by testing the liquid directly squeezed from the wipe compared to measurements of the 5.49% suspension dosed to the wipe. Two wipes from packaging types A and B containing 3.9 mL of spironolactone suspension and two wipes from packaging type A containing 7.8 mL of spironolactone suspension were squeezed by hand and the resulting liquid was measured for spironolactone content.

[0074]

[0087] As seen in Table 3, some water penetrates the fibers of the nonwoven wipe material and deposits spironolactone on the wipe surface. Not all of the water from within the fibers is recovered during the wipe wringing process because the nonwoven material is not completely "dried" by squeezing the dispensed wipe. Because excess water is not adsorbed within the fibers, insufficient water is squeezed out of the fibers to completely detach all of the drug particles attached to the surface of the nonwoven material. Thus, when 3.9 mL of 5.49% spironolactone was dispensed into a wipe in a single-use sachet package, approximately 80% of the suspended spironolactone was recovered from the squeezed wipe. However, when 7.8 mL of the spironolactone nano-sized suspension was dispensed into the wipe, sufficient water was adsorbed into the nonwoven fibers to push the surface-adhered drug particles out of the wipe into a squeezed product similar to the drug product applied to the subject's skin. While neither the 3.9 mL nor the 7.8 mL input volumes are optimal for a topical spironolactone wipe product (the ideal % of spironolactone recovered would be in the range of 95%-105%), Example 4 demonstrated that the optimal dosing volume may be approximately 7 mL, and that a 3.9 mL input volume for a 5 inch by 6 inch size is insufficient to recover 100% of the spironolactone.

[0075] [Table 3]

[0076]

[0089] Example 5

[0090] A clear polyethylene terephthalate (PET) foaming pump containing spironolactone suspension was prepared. One batch of 4.94% (w / w) spironolactone nano-sized suspension in water containing 0.055% dioctyl (diocytl) sodium sulfosuccinate, 1.1% hydroxylpropylcellulose, 1.00% poloxamer 407, 0.10% methylparaben, and 0.01% propylparaben was formulated. The batch was filled into a clear mechanical polyethylene terephthalate (PET) foaming pump. Pre-dispensed product samples were taken before and after shaking to resuspend the API. After shaking, the product from some pumps was dispensed into a tared metering port on a four-decimal balance and directly into a volumetric flask. The amount of product dispensed into the flask was determined by the weight difference. All three samples were measured to determine their API concentrations. The results are set forth in Table 4. Based on these results, the API concentration of the dispensed product is not adversely affected when dispensed from a mechanical foaming pump, but the unit should be shaken prior to dispensing to ensure the API is evenly distributed.

[0077] [Table 4]

[0078]

[0092] Example 6

[0093] A flow-controlled applicator was prepared containing a spironolactone suspension with a white nylon cover over a neoprene sponge and a low-dose spring manufactured by Dab-O-Matic®. One batch of 4.99% (w / w) spironolactone nano-sized suspension in water containing 0.055% dioctyl (diocytl) sodium sulfosuccinate, 1.1% hydroxylpropylcellulose, 0.10% methylparaben, and 0.01% propylparaben was formulated. The batch was filled into a 40 mL high density polyethylene ("HDPE") bottle and capped with an applicator head with the spring removed from the device. The bottle was shaken prior to dispensing and secured to a ring stand with a three-pronged adjustable clamp. A glass beaker was placed under the applicator head to collect the dispensed product. The adjustable clamp was tightened to act as a vice against the bottle to collect the dispensed product.

[0079]

[0094] Samples from both the initial batch and the dispensed product were subjected to measurement testing to determine if the sponge and cover on the applicator head had any adverse effect on the spironolactone concentration of the dispensed product, the results of which are set forth in Table 5. Based on these results, the API concentration of the dispensed product was not adversely affected when dispensed through a flow-controlled applicator head.

[0080] [Table 5]

[0081]

[0096] Example 7

[0097] A dropper in the form of a 29.57 mL (1 oz) round bottle of low density polyethylene ("LDPE") with a controlled dropper tip made of LDPE was prepared containing a spironolactone suspension. A batch of 5.5% (w / w) spironolactone nano-sized suspension in water containing 0.055% dioctyl sodium sulfosuccinate and 1.1% hydroxylpropylcellulose was filled into the dropper bottle. The dropper tip was securely fastened to the neck of the bottle. Prior to dispensing, the bottle was shaken for at least 10 seconds to ensure that the API was adequately suspended. A 3.5 g sample was dispensed directly into a glass vial. A separate sample from the first batch was simultaneously filled into another glass vial to represent the API concentration of the batch prior to dispensing.

[0082]

[0098] Samples taken before and after dispensing were subjected to measurement testing to determine if the controlled dispensing tip had any adverse effect on the spironolactone concentration of the dispensed product, the results of which are set forth in Table 6. Based on these results, the API concentration of the dispensed product was not adversely affected when dispensed through this type of dispensing bottle closure.

[0083] [Table 6]

[0084] [000100] Example 8 [000101] A clear glass 29.57 mL (1 oz) round bottle containing spironolactone suspension was prepared with a plastic fine mist atomizer with a spray volume of 0.14 cc. One batch of spironolactone nano-sized suspension 5.5% (w / w) in water containing 0.055% dioctyl sodium sulfosuccinate and 1.1% hydroxylpropylcellulose was filled into the glass bottle. A plastic pump atomizer was screwed onto the bottle. The bottle was shaken for at least 10 seconds prior to dispensing to ensure that the API was adequately suspended. A 3.5 g sample was dispensed directly into a glass vial. A separate sample from the first batch was simultaneously filled into a separate glass vial to represent the API concentration of the batch prior to dispensing.

[0085] [000102] Samples taken before and after dispensing were subjected to measurement testing to determine if the pump sprayer had any adverse effect on the spironolactone concentration of the dispensed product. The results are set forth in Table 7. Based on these results, the API concentration of the dispensed product was not adversely affected when dispensed via this type of pump sprayer.

[0086] [Table 7]

[0087] [000104] The foregoing description has been presented for purposes of illustration and description. It is not intended to limit the invention to the precise form disclosed. Those skilled in the art will appreciate that modifications and alternatives to the basic description of the invention may be made.

Claims

1. a therapeutically effective amount of spironolactone or a pharmaceutically acceptable salt thereof, wherein the primary particle size distribution of the spironolactone is characterized by a D90 value of less than about 6 μm; and water A pharmaceutical composition comprising:

2. 10. The pharmaceutical composition of claim 1, which is an aqueous suspension.

3. 10. The pharmaceutical composition of claim 1, comprising about 0.10% w / w to about 7.5% w / w of spironolactone or a salt thereof.

4. 10. The pharmaceutical composition of claim 1, further comprising dioctyl sodium sulfosuccinate.

5. 5. The pharmaceutical composition of claim 4, further comprising hydroxyl propyl cellulose.

6. 2. The pharmaceutical composition of claim 1, wherein the primary particle size distribution of spironolactone is characterized by a D90 value of less than about 1 μm.

7. 2. The pharmaceutical composition of claim 1, wherein the primary particle size distribution of spironolactone is characterized by a D90 value of less than about 0.25 μm.

8. 2. The pharmaceutical composition of claim 1, wherein the primary particle size distribution of spironolactone is characterized by a D50 value of less than about 2.7 μm.

9. 2. The pharmaceutical composition of claim 1, wherein the primary particle size distribution of spironolactone is characterized by a D10 value of less than about 1.2 μm.

10. 10. The pharmaceutical composition of claim 1, which is a topical formulation.

11. 10. A package comprising the pharmaceutical composition of claim 1 selected from the group consisting of a sachet containing a wet tissue or wipe containing a suspension, a pump containing a spray or foam, a flow-controlled applicator with a sponge, or a dropper or dropper bottle.

12. a therapeutically effective amount of spironolactone or a pharmaceutically acceptable salt thereof, wherein the primary particle size distribution of the spironolactone is characterized by a D90 value of less than about 6 μm; Dioctyl sodium sulfosuccinate; hydroxypropyl cellulose; and water 10. A pharmaceutical composition consisting essentially of:

13. 13. The pharmaceutical composition of claim 12, which is an aqueous suspension.

14. 13. The pharmaceutical composition of claim 12, comprising about 0.10% w / w to about 7.5% w / w of spironolactone or a salt thereof, about 0.01% w / w to about 1% w / w of dioctyl sodium sulfosuccinate, and about 0.01% to about 1.5% w / w of hydroxylpropylcellulose.

15. 13. The pharmaceutical composition of claim 12, wherein the primary particle size distribution of spironolactone is characterized by a D90 value of less than about 1 μm.

16. 13. The pharmaceutical composition of claim 12, wherein the primary particle size distribution of spironolactone is characterized by a D90 value of less than about 0.25 μm.

17. 13. The pharmaceutical composition of claim 12, wherein the primary particle size distribution of spironolactone is characterized by a D50 value of less than about 2.7 μm.

18. 13. The pharmaceutical composition of claim 12, wherein the primary particle size distribution of spironolactone is characterized by a D10 value of less than about 1.2 μm.

19. 13. A package comprising the pharmaceutical composition of claim 12 selected from the group consisting of a sachet containing a wet tissue or wipe containing a suspension, a pump containing a spray or foam, a flow-controlled applicator with a sponge, or a dropper or dropper bottle.

20. 13. The pharmaceutical composition of claim 12, which is a topical formulation.

21. 1. A pharmaceutical composition for use in a method of treating a hair or skin condition in a subject in need thereof by topical administration to said subject, comprising: (a) spironolactone or a pharmaceutically acceptable salt thereof, wherein the primary particle size distribution of the spironolactone is characterized by a D90 value of less than about 6 μm; and (b) water, the hair or skin condition is selected from the group consisting of acne, alopecia areata, or androgenetic alopecia; Pharmaceutical compositions.

22. 22. The pharmaceutical composition of claim 21, wherein spironolactone is delivered to the pilosebaceous unit.

23. 22. The pharmaceutical composition of claim 21, wherein spironolactone achieves skin penetration of at least 1 mm in the subject.

24. 22. The pharmaceutical composition of claim 21, wherein the pharmaceutical composition is an aqueous suspension.

25. 22. The pharmaceutical composition of claim 21, wherein the composition comprises about 0.10% w / w to about 7.5% w / w of spironolactone or a salt thereof.

26. 22. The pharmaceutical composition of claim 21, wherein the composition further comprises dioctyl sodium sulfosuccinate.

27. 25. The pharmaceutical composition of claim 24, wherein the composition further comprises hydroxyl propyl cellulose.

Images